Drug Development

Avax Expects Clearance To Continue With Its Autologous Cell Vaccines

Published in Vaccine Weekly, November 7th, 2001

Avax Technologies, Inc. has submitted its response to the U.S. Food and Drug Administration's (FDA) request for additional information related to the clinical hold of Avax's clinical trials of M-Vax and O-Vax, autologous cell cancer vaccines.

M-Vax and O-Vax are being studied for the treatment of melanoma and ovarian cancer. In addition, the company has scheduled a meeting with the FDA to discuss issues surrounding the current hold and Avax's planned changes to its product and manufacturing processes.

David L. Tousley, chief operating officer of Avax stated, "We expected that the resolution of the clinical hold would require additional dialogue with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-11-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry